摘要
2型糖尿病的患病率在全球呈上升趋势,亚洲患者超过全球糖尿病患者数的一半。除了降糖作用外,钠-葡萄糖协同转运蛋白2抑制剂对多种危险因素包括血压、体重和肾脏功能等产生有利影响,并为2型糖尿病患者降低心血管疾病风险提供了机会。现对钠-葡萄糖协同转运蛋白2抑制剂治疗亚洲2型糖尿病的研究进展进行总结及分析。
The incidence of type 2 diabetes mellitus has shown a global-dramatic rise.Furthermore,diabetes mellitus in Asia accounts for more than half of the global prevalence.In addition to lowering blood glucose,sodium-glucose cotransporter 2 inhibitors exert favourable effects on multiple risk factors including blood pressure,body weight and renal function.It provides an opportunity to reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus.This review summarized and analyzed the research progress of sodium-glucose cotransporter 2inhibitors in the treatment of Asian type 2 diabetes mellitus patients.
作者
辛玉晶
刘昊凌
XIN Yujing;LIU Haoling(Graduate School of Harbin Medical University,Harbin 150000,Heilongjiang,China;Department of Endocrinology,The First Affiliated Hospital of Harbin Medical University,Harbin 150000,Heilongjiang,China)
出处
《心血管病学进展》
CAS
2020年第3期235-238,共4页
Advances in Cardiovascular Diseases
基金
哈尔滨医科大学研究生科研创新项目(YJSSJCX2018-16HYD)。
